| Schedule of Anti-dilutive Financial Instruments |
The calculation of diluted loss per
share for the six and three months ended June 30, 2024 and June 30, 2023, does not include the shares underlying the following financial
instruments because their effect would be anti-dilutive:
| |
|
Three Months Ended
June 30, |
|
|
Six Months Ended
June 30, |
|
| |
|
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
|
| Options |
|
|
5,071,410 |
|
|
|
5,934,742 |
|
|
|
5,071,410 |
|
|
|
5,934,742 |
|
| Warrants |
|
|
18,252,807 |
|
|
|
9,215,475 |
|
|
|
126,461,307 |
|
|
|
9,215,475 |
|
| Contingent shares |
|
|
2,000,000 |
|
|
|
4,000,000 |
|
|
|
2,000,000 |
|
|
|
4,000,000 |
|
| Redeemable Convertible Preferred Shares |
|
|
256,887,000 |
|
|
|
- |
|
|
|
256,887,000 |
|
|
|
- |
|
|
| Schedule of Basic and Diluted Loss (earnings) Per Share |
The following table presents the computation
of basic and diluted loss (earnings) per share:
| |
|
Three Months Ended
June 30, |
|
|
Six Months Ended
June 30, |
|
| |
|
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
|
| Basic loss (earnings) per share of common stock |
|
|
|
|
|
|
|
|
|
|
|
|
| Numerator: |
|
|
|
|
|
|
|
|
|
|
|
|
| Net loss (income) |
|
|
(4,471 |
) |
|
|
6,411 |
|
|
|
12,856 |
|
|
|
12,772 |
|
| Amount allocated to Redeemable Convertible Preferred Shares |
|
|
(3,516 |
) |
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Net loss (income) attributable to shares of common stock |
|
|
(955 |
) |
|
|
6,411 |
|
|
|
12,856 |
|
|
|
12,772 |
|
| Denominator: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of shares of common stock outstanding |
|
|
69,806,447 |
|
|
|
44,057,875 |
|
|
|
66,056,536 |
|
|
|
36,215,587 |
|
| Number of shares upon Pre-Funded Warrants exercise |
|
|
- |
|
|
|
7,495,048 |
|
|
|
- |
|
|
|
5,644,751 |
|
| Number of shares upon Fully vested Warrants exercise |
|
|
2,974 |
|
|
|
- |
|
|
|
2,974 |
|
|
|
- |
|
| Total weighted-average number of shares of common stock, shares upon Pre-Funded Warrants and Fully vested Warrants exercise used in computing basic loss (earnings) per share |
|
|
69,809,421 |
|
|
|
51,552,923 |
|
|
|
66,059,510 |
|
|
|
41,860,338 |
|
| Basic loss (earnings) per share of common stock |
|
|
(0.01 |
) |
|
|
0.12 |
|
|
|
0.19 |
|
|
|
0.31 |
|
| Diluted net loss per share of common stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Numerator: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net loss (income) |
|
|
(4,471 |
) |
|
|
6,411 |
|
|
|
12,856 |
|
|
|
12,772 |
|
| Change in fair value of Private Placement Warrants |
|
|
11,868 |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Diluted net loss |
|
|
7,397 |
|
|
|
6,411 |
|
|
|
12,856 |
|
|
|
12,772 |
|
| Denominator: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Weighted-average number of shares of common stock outstanding |
|
|
69,809,421 |
|
|
|
51,552,923 |
|
|
|
66,059,510 |
|
|
|
41,860,338 |
|
| Private Placement Warrants |
|
|
37,692,511 |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Weighted-average number of shares of common stock outstanding, after giving effect to dilutive securities |
|
|
107,501,932 |
|
|
|
51,552,923 |
|
|
|
66,059,510 |
|
|
|
41,860,338 |
|
| Diluted net loss per share of common stock |
|
|
0.07 |
|
|
|
0.12 |
|
|
|
0.19 |
|
|
|
0.31 |
|
|